ProMetic in development accord with Abraxis

ProMetic Life Sciences (TSX:PLI) and Abraxis BioScience (NASDAQ: ABII) of Los Angeles have entered into a collaboration agreement to develop and commercialize various applications using ProMetic’s prion capture technology platform to improve the safety profile of blood-derived therapeutics. Under the accord, both companies will equally share the cost for the development of new applications as well [...]

British agency recommends ProMetic’s blood filter

ProMetic Life Sciences Inc. (TSX:PLI) and MacoPharma won the nod of an advisory committee on the safety of blood, tissues and organs, an independent committee that advises Britain’s Department of Health, for adoption of the P-Capt prion reduction filter to pre-treat red blood cells destined for children born since 1996. The filter, which cleans blood [...]